Mumbai, India

Rajendrakumar Joshi

USPTO Granted Patents = 4 

Average Co-Inventor Count = 7.2

ph-index = 4

Forward Citations = 34(Granted Patents)


Company Filing History:


Years Active: 2007-2012

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Innovations and Contributions of Rajendrakumar Joshi

Introduction

Rajendrakumar Joshi is a notable inventor based in Mumbai, India. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that inhibit cyclin-dependent kinases. With a total of four patents to his name, his work has implications for cancer treatment and other diseases.

Latest Patents

One of Rajendrakumar Joshi's latest patents focuses on inhibitors of cyclin-dependent kinases and their use. This invention relates to novel compounds, specifically chromenone derivatives, designed to inhibit cyclin-dependent kinases. The patent outlines processes for preparing these compounds and methods for their application in treating diseases that can be managed through the inhibition of cyclin-dependent kinases, such as cancer. Additionally, it discusses the formulation of pharmaceutical compositions containing these compounds, either alone or in combination with other active agents.

Career Highlights

Throughout his career, Rajendrakumar Joshi has worked with prominent companies in the pharmaceutical sector, including Piramal Healthcare Limited and Piramal Life Sciences Ltd. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Rajendrakumar Joshi has collaborated with several professionals in his field, including Bansi Lal and Kalpana Sanjay Joshi. These collaborations have likely enriched his research and development efforts.

Conclusion

Rajendrakumar Joshi's contributions to the field of medicinal chemistry, particularly through his innovative patents, highlight his role as a significant inventor in the fight against diseases like cancer. His work continues to influence the development of new therapeutic agents.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…